Medpace

The healthcare sector is seen as the next big market for AI, with Medpace and Thermo Fisher named as holdings in a US model portfolio. The biotech sector in particular stands to benefit, as AI identifies drug candidates more quickly, predicts protein structures, and makes therapies more targeted. This could turn early drug research from lengthy testing into a data-driven selection process. » Mais em finanzen.net

Medpace, a global contract research organization and full-service partner for clinical trials, reported an outstanding second quarter. The company provides study design, clinical monitoring, biostatistical analysis and integrated lab services and focuses on small and mid-sized biotech firms. Medpace is seen as a potential winner from AI adoption in biotechnology, as rising numbers of clinical trials could accelerate demand growth for its services. » Mais em finanzen.net

Medpace reports revenue of $707.3 million (+17.2%) for the second quarter of 2026 and a 28.2% increase in net order intake, improving the predictability of its business base. The company confirms full-year guidance of up to $2.89 billion for 2026. The news triggered a roughly 16% jump in the share price, pushing the stock toward its all-time high. » Mais em finanzen.net